CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

NCT04637763 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
Lymphoma
B Cell Lymphoma
B Cell Non-Hodgkin's Lymphoma

Interventions

GENETIC: CB-010
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Caribou Biosciences, Inc.